You are here: Industry Insights > acadia

News List

Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia americanpharmaceuticalreview
April 09, 2021
Acadia Pharmaceuticals Inc. announced that the Company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its supplemental New Drug Application (sNDA) for NUPLAZID® (pimavanserin) for the treatment ...
Acadia pulls plug on pimavanserin for adjunctive MDD pharmatimes
July 24, 2020
Acadia Pharmaceuticals has terminated development of pimavanserin for major depressive disorder (MDD) after the drug failed to hit trials in this setting.
Acadia teams up with Michael J. Fox Foundation for local, patient-focused Parkinson's events fiercepharma
June 28, 2019
Acadia Pharmaceuticals is taking Parkinson’s disease education on the road in a partnership with the Michael J. Fox Foundation. The “Parkinson’s IQ + You” series will traverse the country through this year and next, connecting with local community resourc
Acadia, Neurocrine Could Be Next Takeovers Among Biotech Stocks firstwordpharma
March 03, 2019
Needham analyst Alan Carr identified Acadia Pharmaceuticals and Neurocrine Biosciences as potential takeover targets among biotech firms, Investor's Business Daily reported Friday.
Acadia shares hit by media doubts over Parkinson’s drug pharmaphorum
April 12, 2018
Shares in US biotech Acadia have fallen sharply following a news story linking its Parkinson’s drug Nuplazid with patient deaths.
Media reports over Parkinson’s drug risk hit Acadia hard pharmafile
April 11, 2018
The death toll from taking Acadia Pharmaceutical company Nuplazid, the stock price of this biotechnology company dropped from 35 to 27 in just a few weeks
Acadia launches Parkinson’s campaign to shine light on psychosis symptoms fiercepharma
November 28, 2017
A new disease awareness campaign shines a light on the hallucinations and delusions that can affect half of people who have Parkinson’s disease.
ACADIA Pharmaceuticals Appoints Executive Vice President, Chief Commercial Officer americanpharmaceuticalreview
April 01, 2017
ACADIA Pharmaceuticals Inc.announced Michael J. Yang has joined ACADIA as Executive Vice President and Chief Commercial Officer.